earuphoria.
All podcasts
Business · Investing

Hims House

Jonathan Stern
Rights holder? Report thishimshouse.substack.com

Episodes

November 18, 2026 · Episode 88

🚨 EXCLUSIVE: Max Marchione, Superpower CEO, on the peptides launch and how he's thinking about Hims

Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com/himshouse In episode 88, Jonathan Stern talks with Max Marchione, co-founder and CEO of Superpower, back for his third appearance on the show. Two days after HHS cleared the way for pharmacies to make BPC-157, TB-500, and four other peptides, Superpower started taking pre-orders. We get into pricing and margins, where peptide prices go by 2030, and whether Hims' California peptide factory is a real edge or a marketing play. Then we turn to Hims: what is going...

November 12, 2026 · Episode 87

Hims Q3 earnings recap: "Most disappointing quarter so far" + why Brian Birnbaum is still bullish

Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com/himshouse In episode 87, Jonathan Stern talks with Brian Birnbaum, "The Psycho Analyst," after a brutal week for the stock. We discuss Q3 earnings, which saw subscribers fall for the first time in company history. Plus, Ro disclosed $3B in annual recurring revenue, now ahead of Hims in the U.S. Brian calls Q3 the most disappointing quarter he's seen so far, but still sees Hims as a venture bet in public markets, building something Ro isn't...

November 2, 2026 · Episode 86

🚨 BPC-157 and five other peptides just got the green light: "It's going to be a knife fight"

Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com/himshouse Subscribe to Hims House: https://himshouse.com Follow us: https://x.com/himshouse https://x.com/jonathanrstern https://x.com/jefftangx In episode 86, Jonathan Stern talks with Jeff Tang, a Y Combinator founder who sold his longevity meal prep company to Bryan Johnson and now hosts Peptide Parties in SF and LA Jeff thinks Hims is right...

October 29, 2026 · Episode 85

Why Hims & Hers may be the most asymmetric opportunity in the entire stock market

Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com/himshouse Follow us: https://x.com/himshouse https://x.com/jonathanrstern https://x.com/TravisHoium https://youtube.com/@asymmetricinvesting https://asymmetric-investing.beehiiv.com In episode 85, Jonathan Stern talks with Travis Hoium, founder of Asymmetric Investing, who started buying Hims in spring 2024 and has never sold a share. Travis explains why he calls Hims "the modern pharma company," with the doctor and...

October 20, 2026 · Episode 84

Why payment processors treat peptides as "riskier than gambling", per gray-market peptide CEO

Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com FDA warning letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026 In episode 84, Jonathan Stern talks with Zak David, founder of Peptide Partners, one of the largest research-peptide sellers in the US. This is Zak's first and only interview discussing Peptide Partners' FDA warning letter! We get into why payment processors consider research peptides riskier than gambling, what advice he'd give Hims, and whether the gray market will be even bigger...

October 15, 2026 · Episode 83

Are Peptides Coming By End Of Year?

Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com In episode 83, Jonathan Stern talks with Scott Brunner, CEO of the Alliance for Pharmacy Compounding, the trade group for more than 600 compounding businesses, about the WaPo report that the administration may let pharmacies sell certain peptides before a formal rule is finished. Brunner says he thinks an announcement is "highly likely" before EOY, and he wants conditions on it: ingredients only from FDA-registered wholesalers, a clearer warning to patients, and reports of serious side effects. <...

October 8, 2026 · Episode 82

Brazil's 2nd-largest telehealth CEO on how Hims & Hers should enter Brazil 🇧🇷

Thanks to our partner: Superpower - https://superpower.com In episode 82, Jonathan Stern talks with Abrahão Fecury, co-founder and CEO of Eles & Elas, a Brazilian telehealth company built on the Hims playbook and now at about R$4.5 million (~$1 million USD) in annual revenue, growing about +10% a month. Weight loss is about 70% of that (compounded tirzepatide) at a 54% gross margin, with hair loss and mental health smaller and more profitable. Fecury walks through cash-pay pharmacies, Meta and WhatsApp customer acquisition, and how ANVISA's summer ban on Voy changed the category. We close with a d...

October 1, 2026 · Episode 81

Finnrick CEO on gray market peptides, fake bodega vials, and China's manufacturing prowess

Thanks to our partner:Superpower - https://superpower.com

September 16, 2026 · Episode 80

OpenLoop CEO: the peptide gray market is 2-3x bigger than analyst estimates, likely $6-8 billion

Thanks to our partner:Superpower - https://superpower.com In episode 80 of Hims House, Jonathan Stern talks with Dr. Jon Lensing, co-founder and CEO of OpenLoop, the white-label company that runs telehealth behind the scenes for other brands. Lensing started OpenLoop out of the University of Iowa's medical school and says the platform will see more than 8 million patients this year and treat more than a million a month, across 400-plus brands from telehealth companies to grocery stores, dating apps, and gyms. He said he thinks GLP-1s will become a default medication the way statins did...

September 3, 2026 · Episode 79

HIMS stock token hit $132 on Robinhood over the weekend due to ... $BONER coin?! 😳

Thanks to our partner:Superpower - https://superpower.com 🚨 WARNING: This is not a typical Hims House podcast! I wanted to do this interview because what happened on Robinhood Chain this weekend directly affected $HIMS -- and I think Hims investors should at minimum understand what happened. Jonathan Stern talks with Eric, an Ethereum OG and the world's largest $BONER holder, and Yoni, co-founder of Long.xyz, about BONER — a memecoin on Robinhood Chain paired with the $HIMS stock token. BONER reached roughly 12,000 holders in five days and helped make Hims a top-15 Robinhood stock token...

September 2, 2026 · Episode 78

🚨 THE FTC SUES HIMS & HERS -- Full breakdown with Gaston Kroub

Thanks to our partner:Superpower - https://superpower.com Jonathan Stern talks with Gaston Kroub, founding partner of K2K Law, registered patent attorney, and Hims House's resident legal expert on his third appearance, about the FTC's July 29 federal complaint against Hims & Hers. Kroub calls the filing a public "marketing document" aimed at a quick settlement and ranks three allegation buckets: health data sharing with Meta and Snap as the most exposure, hard cancellation under ROSCA (Restore Online Shoppers' Confidence Act) second, charging before a real consultation as the least dangerous. The case is in the Northern...

August 26, 2026 · Episode 77

Bijan Salehizadeh - Eli Lilly's War on Compounded GLP-1s, Peptides, Retatrutide, and Hims vs Ro

Thanks to our partner:Superpower - https://superpower.com In episode 77, Jonathan Stern talks with Dr. Bijan Salehizadeh -- physician and managing director of NaviMed Capital, former pharma venture investor, founding investor in Auris Health. Bijan holds no position in HIMS. The conversation opens on the FDA: why Heidi Overton is "moldable clay," her 30-40% confirmation odds, and why pharma prefers interim commissioner Kyle Diamantis. They then move to Eli Lilly's multi-front war on compounded GLP-1s, the ReviveRx suit, the effort to pull semaglutide and tirzepatide off the 503B bulks list, and Bijan's theory of a "...

August 7, 2026 · Episode 76

Enhanced Group CEO: Hot peptide summer is coming — but likely not till 2027

Thanks to our partner:Superpower - https://superpower.com Max's recent essays on peptides: https://maximilianbmartin.substack.com/p/six-peptides-one-signal-washington https://maximilianbmartin.substack.com/p/the-peptide-moment-is-here-enhanced In episode 76 of Hims House, Jonathan Stern hosts Maximilian Martin, CEO of Enhanced Group ( $ENHA ), the newly public company behind the Enhanced Games and the Live Enhanced telehealth platform. Martin grades the inaugural games ten weeks out — 42 athletes, 21 personal bests, one world record, and $32M in contracted sponsorship — and argues the 40% stock price selloff that occurred after the Games is m...

July 27, 2026 · Episode 75

🚨 FDA committee votes "YES" on 6 of 7 peptides — here's what happens next, with Dr. Alex Tatem

Thanks to our partner:Superpower - https://superpower.com In episode 75 of Hims House, Jonathan Stern talks with Dr. Alex Tatem, a board-certified urologist who has worked with peptides for 12 years and paid his own way to Silver Spring, MD, to testify on all 7 peptides before the FDA's Pharmacy Compounding Advisory Committee. The panel overruled the FDA's own scientists and recommended six of seven for the 503A Bulks List — DSIP the lone no — and Tatem describes what the national media coverage missed: specifically, briefing documents that omitted the peptide data entirely. He explains why the...

July 15, 2026 · Episode 74

The FDA peptides vote is days away. This insider expects approval

Thanks to our partner:Superpower - https://superpower.com In episode 74, Jonathan Stern sits down with Dr. Jesse Morse, a board-certified family and sports medicine physician, longtime peptide prescriber who helped assemble safety evidence for the upcoming PCAC review. They discuss the FDA briefing recommending against adding seven peptides to the 503A bulks list and how the 2023 restrictions pushed demand into gray and black markets. Morse breaks down the 7 peptides under review -- BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax -- including their proposed uses, safety concerns, and his approval odds for each...

July 7, 2026 · Episode 73

Ryan MacDonald: Peptides could be a $30B+ market, and Hims is positioned to win meaningful share

Thanks to our partner:Superpower - https://superpower.com In Hims House episode 73, Jonathan Stern talks with Needham’s Ryan MacDonald, the lead Hims & Hers analyst with a $35 price target and Buy rating. They break down the latest peptide news, how the FDA/PCAC process actually works, and why peptides may be more of a 2027 revenue story for major telehealth platforms like Hims. They also size the peptide opportunity, debate Hims’ potential share, and dig into GLP-1s, the Novo partnership, branded vs compounded economics, competition, valuation, short interest, insider signals, and the catalysts that...

July 1, 2026 · Episode 72

🚨 EXCLUSIVE: Hims board member David Wells on why he bought $1.2M of Hims

Thanks to our partner:Superpower - https://superpower.com In episode 72 of Hims House, Jonathan Stern interviews David Wells, Hims board member and former Netflix CFO, about his recent $1.2 million open-market purchase of Hims shares. Wells explains why he believes the company is at an inflection point after the Novo dispute and why the market may be missing the larger healthcare platform story. He discusses Hims’ mission, the broken cost and access structure of U.S. healthcare, and why he focuses more on longer-term cohorts and customer value than quarter-to-quarter CAC. The conversation covers th...

June 24, 2026 · Episode 71

Hedge funder Ignacio Canto on retail cults, Hims as Costco + Netflix, and why Hims has 10x upside

Thanks to our partner:Superpower - https://superpower.com In Hims House episode 71, Jonathan Stern sits down with hedge fund manager Ignacio Canto -- founder & portfolio manager at X-Square Capital, which held over 420k Hims shares as of Q1. Canto traces his interest back years, through personal product discovery and his late father's perspective as a urologist, and frames Hims as a platform business attacking a broken, expensive, and slow healthcare system. He explains why he never considered selling through the Novo Nordisk lawsuit, then lays out the moats he cares about: network effects...

June 16, 2026 · Episode 67

Hedge fund manager Imran Khan bought more Hims at its most hated moment -- here's why

Thanks to our partner:Superpower - https://superpower.com In Hims House episode 70, Jonathan Stern sits down with hedge fund manager Imran Khan, founder and CIO of Proem Asset Management and a Hims shareholder (110,000 shares as of March 31). Khan lays out his investment framework -- long-term growth potential, execution track record -- and argues that Hims' core asset is its loyal customer base and its ability to stack new products and services on top of it, with execution as the main bear case. Drawing on his years at Snap as Chief Strategy Officer, he...

June 10, 2026 · Episode 69

Cremieux - Half of America could be on GLP-1s by 2030 (and why peptides are probably overhyped)

In episode 69 of Hims House, Jonathan Stern welcomes back researcher and data analyst Cremieux to take stock of the GLP-1 and peptides market. Cremieux points to Epic's new EHR dashboard as the best live read on adoption, backing estimates that roughly one in eight adults are on GLP-1s and one in five have tried them -- with cost and stigma holding back uptake until semaglutide generics arrive around 2031. They also dig into the next wave of GLP-1s, spotlighting glucagon combos like servadutide and mazdutide for dramatic liver-fat reductions, plus retatrutide's standout weight-loss numbers. Cremieux pushes back on...

Similar podcasts